• Home
• Find A Doctor
• Primary Children's
• Contact Us

Arthur R. Brothman, PhD, FACMG Professor

---

• University of Arizona - B.S. Biology

• University of Arizona - M.S. Genetics

• University of Arizona - Ph.D. Genetics

• Columbia University - Fellowship, Human Genetics and Development

• Los Alamos National Lab - Experimental Path. Group

• Clinical Cytogenetics

• American Board of Medical Genetics

• Director Cytogenetics Lab - University of Utah School of Medicine

• Medical Director Cytogenetics - Associated Regional and University Pathologists

• Adjunct Professor, Human Genetics - University of Utah

• Professor, Pediatrics - University of Utah

• NIH Cytogenetic Analysis of Cells Derived from Prostatic Carcinoma

• NIH Cancer Center Support Grant

• NIH Cytogenetics of Leukemia Studies

• Cap Cure Analysis of Archival Prostate Tumors by FISH

• NIH Molecular and Cytogenetic Analysis of Prostate Carcinoma

• Interstitial deletion 8q11.2-q13 with congenital anomalies suggestive of CHARGE syndrome.
  CB Arrington, H Zhou, AR Brothman, DH Viskochil.
  Am. J. Med. Genet. 133A:326-330, 2005.

• Karyotype/phenotype correlations in duplication 4q: evidence for a critical region within 4q27-28 for preaxial defects.
  Battaglia A, Chen Z, Brothman, AR, Morelli S, Palumbos JC, Carey JC, Hudgins L, Disteche, C.
  Am J Med Genet. 134(3):334-337,2005.

• Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?
  AR Brothman, G Swanson, TM Maxwell, J Cui, KJ Murphy, J Herrick, VO Speights, J Isaac, LR Rohr.
  Cancer Genetics and Cytogenetics, 156:31-36, 2005.

• 4p terminal deletion and 11p subtelomeric duplication detected by genomic microarray in a patient with Wolf-Hirschhorn Syndrome and an Atypical Phenotype.
  DA Stevenson, JC Carey, BC Cowley, R Mao, P Bayrak-Toydemir, AR Brothman.
  The Journal of Pediatrics, 840-842, 2004.

• Multiple abnormalities detected by dye reversal genomic microarrays in prostate cancer: a much greater sensitivity than conventional cytogenetics.
  JA Pettus, BC Cowley, T Maxwell, B Milash, RA Stephenson, LR Rohr, C Hoff, AR Brothman.
  Cancer Genet.Cytogenetics, 154:110-119, 2004.

The Brothman research laboratory focuses on the cytogenetic and molecular aspects of human prostate cancer, the leading malignancy among U.S. males. Many of the men diagnosed with prostate cancer undergo radical surgery for treatment, yet there are no cellular markers to determine which tumors will be aggressive compared with other tumors that may not be life-threatening. One of the goals of the group is to identify genetic markers that can be predictive of clinical outcome. Recent advances have allowed us to begin understanding some of the basic genetic abnormalities associated with prostate tumor epithelial cells. Our methodologies involve cell culturing systems and conventional cytogenetics, fluorescence in situ hybridization (FISH) using chromosome-specific DNA probes, and genomic microarrays as tools for analysis. We also prepare nuclei from archival specimens to determine potential genetic changes in clinical cases in which there are now follow-up data. Our work involves collaborations with other basic science groups in addition to strong interactions with many of the clinicians involved in the treatment and diagnosis of prostate cancer. As Dr. Brothman is a director of Clinical Cytogenetics in the Division of Medical Genetics, ongoing research is often applied to the clinical testing environment of that laboratory. This allows for the implementation of new techniques and provides for stimulating projects relating to unusual clinical genetics cases.